XML 42 R36.htm IDEA: XBRL DOCUMENT v3.24.3
Collaboration Agreements, License Agreement and Revenues - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail)
 9 Months Ended
Sep. 30, 2024
USD ($)
Europe [Member] | Astellas Agreement [Member]  
Disaggregation of Revenue [Line Items]  
Changes in revenue from changes to estimated variable consideration $ 0
Europe [Member] | Astellas Agreement [Member] | License [Member]  
Disaggregation of Revenue [Line Items]  
Total Consideration 619,000,000
Europe [Member] | Astellas Agreement [Member] | Co Development Information Sharing And Committee Services [Member]  
Disaggregation of Revenue [Line Items]  
Total Consideration 287,700,000
U.S./RoW and China [Member]  
Disaggregation of Revenue [Line Items]  
Changes in revenue from changes to estimated variable consideration 0
U.S./RoW and China [Member] | AstraZeneca Agreements [Member] | License [Member]  
Disaggregation of Revenue [Line Items]  
Total Consideration 344,500,000
U.S./RoW and China [Member] | AstraZeneca Agreements [Member] | Co Development Information Sharing And Committee Services [Member]  
Disaggregation of Revenue [Line Items]  
Total Consideration 625,500,000
U.S./RoW and China [Member] | AstraZeneca Agreements [Member] | China Performance Obligation [Member]  
Disaggregation of Revenue [Line Items]  
Total Consideration 458,100,000
U.S./RoW and China [Member] | AstraZeneca Agreements [Member] | Product [Member]  
Disaggregation of Revenue [Line Items]  
Cumulative Revenue $ 311,100,000